Abstract: The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: A new nitro compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each lower alkyl or lower alkoxy(lower)-alkyl, or ##STR2## is cyclized to form ##STR3## X is --O--, --S-- or --NH--, m is an integer 0 or 1, andR.sup.3 is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl, oxamoyl or a group of the formula: --(Y).sub.n --R.sup.4 wherein Y is --CO--, --SO.sub.2 --, --COCH.sub.2 -- or ##STR4## n is an integer of 0 or 1, and R.sup.4 is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl, and pharmaceutically acceptable salt thereof, which are useful as vasodilators.

Abstract: The present invention provides: a urea-modified carbodiimide represented by the following general formula ##STR1## (wherein each R is a C.sub.1 -C.sub.12 alkyl group or a C.sub.3 -C.sub.10 cycloalkyl group; each Z is a C.sub.1 -C.sub.12 alkylene group, a C.sub.3 -C.sub.10 cycloalkylene group, a C.sub.4 -C.sub.16 alkylene group having a cyclic or non-cyclic structure, or a C.sub.8 -C.sub.16 alkylene group having an aromatic ring; n is an integer of 1-50; and each m is an integer of 1 or 2), and a process for producing the above urea-modified carbodiimide, which comprises (1) reacting an organic aliphatic diisocyanate represented by the following general formulaO.dbd.C.dbd.N--Z--N.dbd.C.dbd.

Abstract: The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin and which have the formula ##STR1## in which: A is a single bond, a group --CH.sub.2 --, a group --CH.sub.2 O--, a group --CH.sub.2 NH--, a group --CH(OH)--, a group --CHF-- or a group --CH(OCH.sub.3)--, andn is equal to 6 or 8,and their addition salts.These novel compounds are useful especially as immunosuppressants. The invention further relates to the method of preparing said compounds.

Abstract: Urea-containing hydroxyethylamine peptide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV Protease.

Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

Abstract: A novel bis-urea compound, preparation process of the compound, and preparation process of 1,3-dialkyl-2-imidazolidinone are disclosed and the disclosure provides a novel preparation process of 1,3-dialkyl-2-imidazolidinone and simultaneously enables effective utilization of N,N',N"-trialkyldiethylentriamine which lacks a large amount use and is desired to develop new application.

Abstract: A novel bis-urea compound, preparation process of the compound, and preparation process of 1,3-dialkyl-2-imidazolidinone are disclosed and the disclosure provides a novel preparation process of 1,3-dialkyl-2-imidazolidinone and simultaneously enables effective utilization of N,N',N"-trialkyldiethylentriamine which lacks a large amount use and is desired to develop new application.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: A new nitro compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each lower alkyl or lower alkoxy(lower)alkyl, or ##STR2## is cyclized to form ##STR3## X is --O--, --S-- or --NH--, m is an integer 0 or 1, andR.sup.3 is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl, oxamoyl or a group of the formula: --(Y).sub.n --R.sup.4whereinY is --CO--, --SO.sub.2 --, --COCH.sub.2 -- or ##STR4## n is an integer of 0 or 1, and R.sup.4 is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl, and pharmaceutically acceptable salt thereof, which are useful as vasodilators.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin. These novel compounds have the formula ##STR1## in which: n is equal to 6 or 8 andA is a single bond, CH.sub.2, CHF, CH(OH), CH(OCH.sub.3), CH.sub.2 NH or CH.sub.2 O,and their addition salts.

Abstract: Urea-containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: A novel cyclopropenone derivative (I) which possesses a potent inhibitory activity against thiol protease such as papain, cathepsin B, cathepsin H, cathepsin L, calpain or the like with excellent properties regarding oral absorbance, tissue transference and cell membrane permeability, and are clinically useful in the treatment of various diseases such as muscular dystrophy, amyotrophy. Also provided are a process for producing the compound (I) and a pharmaceutical composition containing the same.

Abstract: A process for making unsaturated .alpha.-amines from olefins wherein the process includes adding an aminating agent, an olefin and a molybdenum based catalyst to a reaction vessel having a nitrogen atmosphere. The catalyst may be described by the general formula LL'MoO.sub.2, L.sub.2 L'MoO.sub.2, or LL'MoO(X--Y).

Abstract: Novel compounds have been discovered that are particularly effective as nucleation accelerators or boosters when employed with hydrazide nucleators in the formulation of silver halide emulsions for lithographic film. The novel compounds contain bis ureido groups joined by an alkyleneoxy moiety or recurring alkyleneoxy moieties. The 2-nitrogen of each ureido group can carry groups comprising hydrogen, aryl, alkyl or dialkylaminoalkyl, alike or different.

Abstract: Diurea derivatives are provided which can be represented by the following general formula and salts thereof: ##STR1## wherein, R.sup.1 and R.sup.2 are the same or different, and each represents C.sup.1 -10 alkyl group, a C.sup.3 -18 cycloalkyl group, or a lower alkyl group substituted by cycloalkyl radical(s);R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same or different, and each represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, hydrocarbyl aralkyl group, a pyridyl group, or an unsubstituted or substituted phenyl group, the substituents of the phenyl group being selected from a group consisting of lower alkyl radical, halogen atom-substituted lower alkyl radical, halogen atom, nitro radical, amino radical, mono- or di-lower alkylamino radical, lower acylamino radical, hydroxyl radical, lower alkoxy radical and lower acyloxy radical;X represents an oxygen atom or a sulfur atom, and n.sup.1 and n.sup.2 represent an integer of 1 to 6; and wherein at least one of R.sup.3 -R.sup.

Abstract: Novel compounds have been discovered that are particularly effective as nucleation accelerators or boosters when employed with hydrazide nucleators in the formulation of silver halide emulsions for lithographic film. The novel compounds contain bis ureido groups joined by an alkyleneoxy moiety or recurring alkyleneoxy moieties. The 2-nitrogen of each ureido group can carry groups comprising hydrogen, aryl, alkyl or dialkylaminoalkyl, alike or different.

Abstract: A process for making unsaturated .alpha.-amines from olefins wherein the process includes adding an aminating agent, an olefin and a molybdenum based catalyst to a reaction vessel having a nitrogen atmosphere. The catalyst may be described by the general formula LL'MoO.sub.2, L.sub.2 L'MoO.sub.2, or LL'MoO(X-Y).

Abstract: A novel cyclopropenone derivative (I) which possesses a potent inhibitory activity against thiol protease such as papain, cathepsin B, cathepsin H, cathepsin L, calpain or the like with excellent properties regarding oral absorbance, tissue transference and cell membrane permeability, and are clinically useful in the treatment of various diseases such as muscular dystrophy, amyotrophy. Also provided are a process for producing the compound (I) and a pharmaceutical composition containing the same.

Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.

Abstract: The present invention provides a novel class of compounds, useful as gasoline detergent additives, comprising asymmetrical ureas of either a hydrocarbyloxypolyether amine alone, or a hydrocarbyloxypolyether amine and a tertiary aminoalkyl primary amine. The present invention also provides a motor fuel composition containing the novel asymmetrical ureas and further provides a method of synthesizing the asymmetrical ureas of the present invention.

Abstract: Diurea derivatives are provided which can be represented by the following general formula and salts thereof: ##STR1## Illustrative derivatives include 1,3-bis[[1-cycloheptyl-3-(3-pyridyl)ureido]-methyl]benzene, 1,3-bis[[1-cycloheptyl-3-(2-pyridyl)ureido]-methyl]benzene, and 1,3-bis[[1-cycloheptyl-3-(4-pyridyl)ureido]-methyl]benzene.The above compounds inhibit acyl-coenzyme A cholesterol acyltransferase (ACAT enzyme), and thereby control the accumulation of cholesterol ester to the smooth muscle of arterial wall in the blood vessel.

Abstract: The present invention is directed to a process for the preparation of amines containing urethane and urea groups. The amines are produced by reacting A) isocyanate prepolymers containing urethane groups and in which the isocyanate groups are reversibly blocked with secondary monoamines with B) amines having molecular weights of from 60 to 500, which are at least difunctional and which have a total of at least two primary or secondary amino groups, with splitting off of the secondary monoamine. The invention is also directed to the amines so produced and to the use as a hardener for an epoxide resin.

Abstract: New perfluoroaminoether polymers and a process for preparing them which comprises copolymerizing fluorinated olefins with oxaziridines in the presence of ultra-violet radiations or of chemical initiators.

Abstract: Glycerine derivatives of the formula ##STR1## wherein the residues R.sup.1, R.sup.2 and R.sup.3 have the significance given in the description, and their hydrates, which inhibit blood platelet activating factor (PAF), are described.

Abstract: Diurea Derivatives represented by the following general formula and salts thereof: ##STR1## The above compounds inhibit acyl-coenzyme A chloresterol acyl-transferase (ACAT enzyme), and thereby control the accumulation of cholesterol ester to the smooth muscle of arterial wall in the blood vessel.

Abstract: There are disclosed quaternary ammonium salts which are obtainable by reacting basic carbamides containing a quaternizable nitrogen atom with epihalohydrins.These quaternary ammonium salts are particularly suitable for enhancing the color yield and the wet fastness properties of dyeings or printings produced on cellulosic fibre materials with anionic dye, e.g. reactive or direct dyes.

Abstract: A polyahl comprising a backbone having at least one acyclic moiety selected from the group consisting of urea, biuret, thiourea, dithiobiuret, amide, and thioamide; and at least two polyalkyleneoxy moieties; and at least one terminal hydroxyalkyl carbamate group is disclosed. These polyahls may be prepared by contacting a modified polyamide compound containing in its backbone at least one acyclic moiety selected from the group consisting of urea, biuret, thiourea, dithiobiuret, amide, and thioamide wherein the amino groups are sufficiently spaced apart from each other that they do not undergo reaction with a single alkylene carbonate moiety to form a cyclic urea moiety, with a cyclic alkylene carbonate, in amounts thereof and under conditions effective to form the polyahl. Prepolymers and polymers prepared from such polyahls are also disclosed.

Abstract: Diurea derivatives are provided which are represented by the following general formula and salts thereof: ##STR1## The above compounds inhibit acyl-coenzyme A cholesterol acyl-transferase (ACAT enzyme), and thereby control the accumulation of cholesterol ester on the smooth muscle of arterial wall in the blood vessels.

Abstract: There are disclosed quaternary ammonium salts which are obtainable by reacting basic carbamides containing a quaternisable nitrogen atom with epihalohydrins.These quaternary ammonium salts are particularly suitable for enhancing the color yield and the wet fastness properties of dyeings or printings produced on cellulosic fibre materials with anionic dye, e.g. reactive or direct dyes.

Abstract: Hydroxy-terminated substituted diurea derivatives of hydroxy-terminated polyurea derivatives of secondary monoalkylamines and organic diisocyanates and hydroxy-terminated polyurea derivatives of secondary monalkylamines and prepolymers of organic diisocyanates with polyoxyalkylene polyols, such as hydroxy-terminated polyurea derivatives of secondary monoalkylamines and organic diisocyanates having the formula: ##STR1## wherein: R represents an aliphatic or an aromatic group containing from 6 to about 20 carbon atoms,R' represents H or an alkyl group containing 1 to 6 carbon atoms, andn is a positive integer having a value of 1 to 4.

Abstract: New acrylic derivative of urea: monomethylolacrylamidomethyleneurea.Preparation process, according to which acrylamidomethyleneurea is reacted with formaldehyde.Application to the manufacture of additives suitable for use in aminoplastic resins.

Abstract: 4-(N-Substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof are described, as well as methods for the preparation and pharmaceutical compositions of same, which are useful as centrally acting muscarinic agents and are useful as analgesic agents for the treatment of pain, as sleep aids and as agents for treating the symptoms of senile dementia, Alzheimer's disease, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, or similar conditions of cerebral insufficiency characterized by decreased cerebral acetylcholine production or release.

Abstract: Novel isoprenoidamine compounds (I) which show antiulcer activity are provided.

Abstract: Novel polyahls having backbones containing urea, urethane and polyamine moieties and hydroxyl and/or amine terminal groups are prepared by contacting a polyamine such as an aminated polyether polyol or hexamethylene diamine with a cyclic alkylene carbonate such as propylene carbonate under conditions sufficient to form the polyahl and a monoalkylene glycol. The monoalkylene glycol is removed from the reaction mixture in order to drive the reaction to completion.Such polyahls are useful in the preparation of isocyanate-functional prepolymers and polyurea/polyurethanes. The latter are suitably employed as flexible and rigid foams, coatings, RIM elastomers and other applications where conventional polyurethanes are employed.

Abstract: 2-(Disubstituted amino)acetamides of the formula ##STR1## wherein R is alkyl or phenyl; R.sup.1 is selected from the group consisting of amino, alkyl, allyl, substituted carbonyl wherein said substituent is haloalkyl, alkoxycarbonyl, alkylthio, carboxy, alkoxy, alkyl, vinyl, haloanilino, phenylthio, alkylamino, benzylamino, alkoxycarbonylalkyl or substituted carbamyl wherein the substituent is alkyl halocarbanilide; alkylthio thiocarbonyl; or mono-haloanilino carbonylmethylene, alkoxy carbonylmethylene, or carboxymethylene; R.sup.2 is hydrogen, alkyl or phenyl; X is halo or haloalkyl; and n is an integer selected from 1-3, inclusive; the compounds are useful as herbicidal agents.

Abstract: Polyoxyalkylene diamine reaction products which contain as the principle reaction component, a diamine having the formula: ##STR1## wherein R' independently represents hydrogen or methyl and x is a number having an average value of at least 1 to about 60 and a diisocyanate of the formula: ##STR2## The products of the invention are obtained by reacting an excess of polyoxyalkylene diamine with a diisocyanate in the presence of a polar solvent and have the following general structures: ##STR3## where B is alkyl group from diisocyanates, and R' has the same meaning as above.These products are further used to prepare coatings with improved properties by reacting said amine products with isocyanates prepolymers and epoxy material.

Abstract: There is disclosed a family of new vinyl monomers capable of forming polymers by free radical polymerization. The vinyl monomer is of the formula ##STR1## wherein R.sub.1 and R.sub.2 are substituted or unsubstituted hydrocarbons, X is O, NH or NR.sub.3, and R.sub.3 is substituted or unsubstituted hydrocarbon.The intermediates in the synthesis of these monomers are new beta-chloroalanine ureas. The polymers are useful in film and fiber formation and display good toughness. These new vinyl monomers also form a cyclic monomer.

Abstract: The present invention is directed to novel polyhydroxyalkyl oligoureas prepared by condensing urea derivatives with polyamides. The present invention is further directed to polyether polyols prepared by alkoxylating these polyhydroxyalkyl oligoureas. Finally, the present invention is directed to the use of both the polyhydroxyalkyl oligoureas and the polyethers prepared therefrom for use in the production of polyurethanes, particularly rigid foams.

Abstract: There are disclosed compounds of the formulaR.sup.1 -XwhereinR.sup.1 is alkyl of 8-22 carbon atoms;X is ##STR1## R.sup.2 is --(CH.sub.2).sub.n NR.sup.4 R.sup.5 ; R.sup.3 is hydrogen or lower alkyl;R.sup.4 is hydrogen or lower alkyl;R.sup.5 is hydrogen or lower alkyl; andn is 0-7, with the proviso that when X is ##STR2## n is 6-7; and their use in the prevention and/or treatment of conditions such as allergic rhinitis, allergic bronchial asthma and other naso-bronchial obstructive air-passageway conditions, other immediate hypersensitivity reactions such as allergic conjunctivitis and various inflammatory conditions.

Abstract: A high performance water and oil repellant composed of a compound comprising at least two terminal segments and an intermediate segment connecting the terminal segments and having a molecular weight of from 800 to 20,000, each terminal segment containing at least one polyfluoroalkyl group connected by a --CONH-- linking group, said intermediate segment being a urethane oligomer containing at least two --CONH-- linking groups in one molecule, and said terminal segments and intermediate segment being connected by a --CONH-- linking group.

Abstract: Synthetically produced substantially pure biologically active compounds having the general formula ##STR1## wherein R.sub.1 is C.sub.1 -C.sub.20 alkyl, alkenyl, aryl, aralkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcycloalkenyl, or cycloalkenylalkyl;R.sub.2 is hydrogen, C.sub.1 -C.sub.10 alkyl or an amide-substituted alkyl having up to 10 carbon atoms;R.sub.3 is a cyclic, straight or branched chain hydrocarbon group having 2-12 carbon atoms, particularly --(CH.sub.2).sub.n --, wherein n is 2-12; orR.sub.2 and R.sub.3 are linked together to form an alkylene chain; andR.sub.4 is selected from ##STR2## (substituted or unsubstituted carbamimidoyl), ##STR3## (dimethylpyrimidyl), or ##STR4## (carbamyl) wherein each of R.sub.5, R.sub.6, and R.sub.7 is hydrogen or the same or different C.sub.1 -C.sub.8 alkyl group. The compounds are useful as bactericides for a wide variety of bacteria, including S.pyogenes, B.subtilis, K.pneumoniae, M.avium, B.fragilis, C.perfringens and C.albicans.

Abstract: A process for producing compounds containing hydroxy alkyl amide groups by the reaction of a bicyclic amide acetal with a member selected from the group consisting of urea, biuret, thiourea, thiobiuret, alkyl substituted ureas, aryl substituted ureas, alkyl substituted thioureas, aryl substituted thioureas, alkylene ether ureas, arylene ether ureas, alkylene ether tioureas and arylene ether thioureas is disclosed.

Abstract: Novel lipid derivatives of the formula ##STR1## [wherein R.sup.1 is alkyl or alkylcarbamoyl; R.sup.2 is hydrogen, hydroxy which may be substituted, amino which may be substituted or cyclic amino; R.sup.3 is a chemical binding or alkylene which may be substituted; R.sup.4 is hydrogen, alkyl or aralkyl; X and Y are independently O, S or an imino group which may be substituted, and when Y is an imino group, Y, together with the imino group represented by X or R.sup.4, may form a ring; and Z is imino or a nitrogen-containing heterocyclic ring which may be substituted] and salts thereof have inhibiting activity on platelet activating factor and are useful as a preventive or therapeutic agent for a variety of circulatory diseases and allergic disorders and also as an antineoplastic agent.

Abstract: Pesticidally active compounds of the formula ##STR1## in which R.sup.1 is an organic radical,R.sup.2 is hydrogen, trialkylsilyl, a hydrocarbon or acyl radical, andR.sup.3 and R.sup.4 independently are an amino, hydroxyl, hydroximino, alkoxy or like radical.Most of the compounds are new, as are various intermediates therefor.

Abstract: Polyahls comprising(1) a backbone having a random arrangement of(a) a plurality of alkylene urethane and/or(b) alkylene urea moieties and, optionally,(c) a plurality of alkylene carbonate and/or alkyleneoxy moieties, and/or alkylene moieties of greater than 6 carbons, and(2) a plurality of active hydrogen moieties covalently bonded to the backbone or a side chain of the backbone provided that at least one of said active hydrogen moieties is hydroxyl and at least one of said active hydrogen moieties is amino are described.Isocyanate-functional prepolymers are formed by the reaction of these polyahls with polyisocyanates. Polyurethane or polyurea compositions can be formed by the reaction of these isocyanate-functional prepolymers with a polyol or polyamine.